Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionhistone modifying activity

HIPK4 USP22

4.47e-0322992GO:0140993
PathwayREACTOME_SIGNALING_BY_CYTOSOLIC_FGFR1_FUSION_MUTANTS

CUX1 PIK3CA

1.54e-051852M673
PathwayREACTOME_FGFR1_MUTANT_RECEPTOR_ACTIVATION

CUX1 PIK3CA

4.66e-053152M661
PathwayREACTOME_SIGNALING_BY_FGFR1_IN_DISEASE

CUX1 PIK3CA

7.04e-053852M27536
PathwayREACTOME_SIGNALING_BY_FGFR_IN_DISEASE

CUX1 PIK3CA

1.95e-046352M635
PathwayREACTOME_RAC2_GTPASE_CYCLE

PIK3CA ARHGAP32

3.72e-048752MM15600
PathwayREACTOME_RAC2_GTPASE_CYCLE

PIK3CA ARHGAP32

3.81e-048852M41810
PathwayREACTOME_RAC1_GTPASE_CYCLE

PIK3CA ARHGAP32

1.50e-0317552MM15599
PathwayREACTOME_RAC1_GTPASE_CYCLE

PIK3CA ARHGAP32

1.65e-0318452M41809
Pubmed

Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy.

CUX1 PIK3CA

3.01e-052910226633882
GeneFamilyZinc fingers C2H2-type|ZF class homeoboxes and pseudogenes

ZNF408 HIVEP3

2.12e-027186228
CoexpressionAtlasalpha beta T cells, preT.DN3A.Th, Lin-/lo CD25hi CD44- CD28-, Thymus, avg-3

CUX1 HIVEP3 USP22 ARHGAP32

9.55e-0641684GSM791146_500
ToppCell343B-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_0|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)

HIVEP3 USP22

5.76e-041631020ab043b68e8739adcedda01165a3758cd0d22728
ToppCellMild/Remission-B_naive-4|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5)

PIK3CA ARHGAP32

6.19e-04169102c3a6179a64589a370108fea809b157839347759c
ToppCell390C-Myeloid-Macrophage-M2-like_Macrophage_(MARCO_negative)|Myeloid / Donor, Lineage, Cell class and subclass (all cells)

HIVEP3 CATSPERE

6.48e-041731021f725ff16e28636b20ef26f3fa9be8b47c89378d
ToppCellfacs-Skin-Skin_Anagen-18m-Epithelial-epidermal_cell|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CUX1 USP22

6.48e-041731020f9c1d3298e59e6d22bb3306f0f445f490be8bbd
ToppCellB_cells-Naive_B_cells_|B_cells / Immune cells in Kidney/Urine in Lupus Nephritis

HIVEP3 ARHGAP32

6.86e-0417810271ac2eca5cf13a91f86b80690748b0788392dcfc
ToppCellPND28-Immune-Immune_Myeloid-DC-cDC1-cDC1_prolif|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

FASTKD3 ARHGAP32

6.94e-041791029dea57494d59abd6e8abf34e31faf53462ea0fa0
ToppCellPND01-03-samps-Mesenchymal-Matrix_fibroblast-MatrixFB-A|PND01-03-samps / Age Group, Lineage, Cell class and subclass

HIPK4 HIVEP3

7.89e-04191102e7c605b56934d1383237c1f946dbccef25d91368
ToppCellMild/Remission-B_naive-8|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5)

HIVEP3 PIK3CA

8.22e-041951020a3221e4d1fa31a35868bdda0f0cc873c233b407
ToppCellControl-B_naive-8|Control / disease group and sub_cluster of B and Plasma cells(res = 0.5)

HIVEP3 PIK3CA

8.30e-0419610254074da84000e4749ade8acc542f05a275bf829f
ToppCellParenchymal-NucSeq|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations

CUX1 ARHGAP32

8.47e-041981021996373bdccc55aac347d349bd22f6aad6d0c668
ToppCellFetal_brain-fetalBrain_Zhong_nature-GW26-Neuronal-GABAergic_neurons|GW26 / Sample Type, Dataset, Time_group, and Cell type.

CUX1 HIVEP3

8.64e-04200102bad32a95b759fad509401b07bc96a56687c2a592
DrugTGX-221

CUX1 PIK3CA

3.88e-06892CID009907093
DrugPtdIns(3)P

CUX1 PIK3CA ARHGAP32

3.62e-0517593CID000643964
DrugAC1OAGFW

CUX1 PIK3CA ARHGAP32

4.21e-0518493CID006857352
DrugMeticrane [1084-65-7]; Up 200; 14.6uM; PC3; HT_HG-U133A

CUX1 ZNF408 HIVEP3

4.78e-05192931792_UP
DrugMebhydroline 1,5-naphtalenedisulfonate [6153-33-9]; Down 200; 4.8uM; HL60; HT_HG-U133A

CUX1 HIVEP3 ARHGAP32

5.16e-05197931333_DN
DrugClindamycin hydrochloride [21462-39-5]; Down 200; 8.6uM; PC3; HT_HG-U133A

ZNF408 PIK3CA ARHGAP32

5.31e-05199932057_DN
DrugPI-103

CUX1 PIK3CA

6.85e-053292CID009884685
DrugMolPort-016-580-972

CUX1 PIK3CA

1.75e-045192CID009938589
Drugmethyl 2,5-dihydroxycinnamate

CUX1 PIK3CA

4.00e-047792CID000003248
DrugPtdIns(3,4)P

CUX1 PIK3CA

5.11e-048792CID000643960
DrugPtdIns(4)P

PIK3CA ARHGAP32

7.29e-0410492CID000643965
Drug8-ethoxycaffeine

CUX1 PIK3CA

8.29e-0411192CID000011347
DrugLes T

CUX1 ARHGAP32

1.02e-0312392CID000003189
DrugPI(3,4,5)P3

CUX1 PIK3CA

1.47e-0314892CID000643963
Drugmonomethyl phthalate

CUX1 PIK3CA

1.61e-0315592CID000020392
Drugdecanamide

CUX1 PIK3CA

1.73e-0316192CID000075347
DrugAC1L1CV3

CUX1 PIK3CA

1.91e-0316992CID000002076
Drughydroxyapatite

USP22 ARHGAP32

1.95e-0317192CID000014781
DrugSAHA; Down 200; 10uM; MCF7; HT_HG-U133A

ZNF408 USP22

2.06e-03176926980_DN
DrugEmetine dihydrochloride [316-42-7]; Down 200; 7.2uM; MCF7; HT_HG-U133A

PIK3CA ARHGAP32

2.09e-03177924827_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

ZNF408 USP22

2.11e-03178921471_DN
DrugPerphenazine [58-39-9]; Up 200; 10uM; PC3; HG-U133A

ZNF408 ARHGAP32

2.28e-03185921956_UP
Drugtyrphostin AG-825; Up 200; 25.2uM; MCF7; HT_HG-U133A_EA

CUX1 ZNF408

2.40e-03190921114_UP
DrugTriflupromazine hydrochloride [1098-60-8]; Up 200; 10.2uM; PC3; HT_HG-U133A

CUX1 HIVEP3

2.42e-03191921813_UP
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HG-U133A

ZNF408 HIVEP3

2.45e-03192921400_DN
DrugPiromidic acid [19562-30-2]; Down 200; 13.8uM; HL60; HT_HG-U133A

CUX1 HIVEP3

2.47e-03193922996_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HT_HG-U133A

CUX1 HIVEP3

2.47e-03193921284_DN
DrugIsradipine [75695-93-1]; Down 200; 10.8uM; PC3; HT_HG-U133A

HIVEP3 ARHGAP32

2.50e-03194926347_DN
DrugCGX 0596987; Down 200; 20uM; PC3; HT_HG-U133A

ZNF408 HIVEP3

2.50e-03194926417_DN
DrugDexamethasone acetate [1177-87-3]; Down 200; 9.2uM; HL60; HG-U133A

ZNF408 ARHGAP32

2.50e-03194921396_DN
Drugnordihydroguaiaretic acid; Down 200; 1uM; PC3; HT_HG-U133A

ZNF408 HIVEP3

2.50e-03194921223_DN
DrugDihydroergotamine tartrate [5989-77-5]; Down 200; 3uM; PC3; HT_HG-U133A

HIVEP3 ARHGAP32

2.53e-03195924502_DN
DrugTrichlormethiazide [133-67-5]; Down 200; 10.6uM; PC3; HT_HG-U133A

ZNF408 HIVEP3

2.53e-03195924198_DN
DrugBepridil hydrochloride [74764-40-2]; Down 200; 10uM; HL60; HT_HG-U133A

CUX1 HIVEP3

2.53e-03195921274_DN
DrugEsculetin [305-01-1]; Down 200; 22.4uM; HL60; HT_HG-U133A

ZNF408 ARHGAP32

2.53e-03195923120_DN
DrugCefazolin sodium salt [27164-46-1]; Down 200; 8.4uM; PC3; HT_HG-U133A

ZNF408 ARHGAP32

2.53e-03195927385_DN
DrugEthambutol dihydrochloride [1070-11-7]; Down 200; 14.4uM; HL60; HG-U133A

CUX1 ARHGAP32

2.53e-03195921981_DN
Drugwortmannin from Penicillium funiculosum; Down 200; 0.01uM; PC3; HT_HG-U133A

ZNF408 ARHGAP32

2.53e-03195921243_DN
DrugKhellin [82-02-0]; Down 200; 15.4uM; HL60; HG-U133A

CUX1 ZNF408

2.53e-03195922004_DN
DrugAtovaquone [95233-18-4]; Down 200; 11uM; PC3; HT_HG-U133A

ZNF408 HIVEP3

2.53e-03195924201_DN
DrugRapamycin; Down 200; 0.1uM; PC3; HT_HG-U133A

ZNF408 ARHGAP32

2.53e-03195921207_DN
DrugPropofol [2078-54-8]; Down 200; 22.4uM; PC3; HT_HG-U133A

ZNF408 HIVEP3

2.53e-03195926707_DN
DrugHarpagoside [19210-12-9]; Down 200; 8uM; HL60; HT_HG-U133A

ZNF408 HIVEP3

2.55e-03196922935_DN
DrugAlverine citrate salt [5560-59-8]; Down 200; 8.4uM; PC3; HT_HG-U133A

ZNF408 ARHGAP32

2.55e-03196922110_DN
DrugNabumetone [42924-53-8]; Up 200; 17.6uM; HL60; HT_HG-U133A

CUX1 HIVEP3

2.55e-03196923108_UP
DrugAminophylline [317-34-0]; Down 200; 9.6uM; PC3; HT_HG-U133A

CUX1 HIVEP3

2.55e-03196926295_DN
DrugXylometazoline hydrochloride [1218-35-5]; Down 200; 14.2uM; HL60; HG-U133A

CUX1 ZNF408

2.55e-03196921423_DN
DrugAtropine-N-oxide hydrochloride [4574-60-1]; Down 200; 11.8uM; HL60; HG-U133A

ZNF408 HIVEP3

2.55e-03196921370_DN
DrugRapamycin; Down 200; 0.1uM; HL60; HT_HG-U133A

HIVEP3 ARHGAP32

2.55e-03196922667_DN
DrugSulfadimethoxine [122-11-2]; Up 200; 12.8uM; MCF7; HT_HG-U133A

HIVEP3 ARHGAP32

2.55e-03196923441_UP
Drugprochlorperazine dimaleate salt; Down 200; 10uM; HL60; HT_HG-U133A

ZNF408 ARHGAP32

2.55e-03196921156_DN
DrugAsiaticoside [16830-15-2]; Up 200; 4.2uM; HL60; HT_HG-U133A

CUX1 HIVEP3

2.55e-03196922943_UP
DrugApomorphine hydrochloride hemihydrate [41372-20-7]; Down 200; 6.4uM; HL60; HG-U133A

ZNF408 PIK3CA

2.55e-03196922005_DN
DrugAmyleine hydrochloride [532-59-2]; Up 200; 14.8uM; PC3; HG-U133A

ZNF408 HIVEP3

2.58e-03197921909_UP
DrugPindolol [13523-86-9]; Down 200; 16.2uM; HL60; HG-U133A

ZNF408 HIVEP3

2.58e-03197921392_DN
DrugRapamycin; Down 200; 0.1uM; HL60; HT_HG-U133A

ZNF408 ARHGAP32

2.58e-03197921183_DN
DiseaseCutaneous Melanoma

CUX1 PIK3CA

8.42e-0541102C0151779
DiseaseMalignant neoplasm of breast

FASTKD3 CUX1 CATSPERE PIK3CA

3.07e-041074104C0006142
Diseaseeye color

HIVEP3 ARHGAP32

4.07e-0490102EFO_0003949
DiseaseAdenocarcinoma of large intestine

CUX1 PIK3CA

4.63e-0496102C1319315
DiseaseMalignant Neoplasms

CUX1 PIK3CA

8.21e-04128102C0006826
Diseasestomach cancer (is_marker_for)

CUX1 PIK3CA

1.01e-03142102DOID:10534 (is_marker_for)
DiseaseColorectal Carcinoma

CUX1 HIVEP3 PIK3CA

1.42e-03702103C0009402
Diseasemelanoma

CUX1 PIK3CA

3.03e-03248102C0025202

Protein segments in the cluster

PeptideGeneStartEntry
IKGFSKKGCHHHDFS

CATSPERE

711

Q5SY80
AACKAHHFFKRNPHP

HIPK4

241

Q8NE63
TFCAKKFADHLHKFH

CUX1

651

Q13948
KGHFPKMAECAHFHY

ARHGAP32

111

A7KAX9
HIDFGHFLDHKKKKF

PIK3CA

931

P42336
FFHCTSEGNKEKPHH

SCP2D1-AS1

136

Q9BR46
EPFGVKFHHAHCKKF

FASTKD3

51

Q14CZ7
KFHHAHCKKFHSKNG

FASTKD3

56

Q14CZ7
FFGCFTKKHIHEHAK

USP22

81

Q9UPT9
CHLKKHAFVHTGHKP

ZNF408

366

Q9H9D4
HCHFAFKTKGNLTKH

HIVEP3

1786

Q5T1R4